Review anchor
Eukaryotic translation initiation factor 4B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Eukaryotic translation initiation factor 4B
CHEMBL3308928
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Eukaryotic translation initiation factor 4B as ChEMBL target CHEMBL3308928, mapped to UniProt P23588. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3308928
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23588
Eukaryotic translation initiation factor 4B
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Eukaryotic translation initiation factor 4B matters
Eukaryotic translation initiation factor 4B is reviewed as Eukaryotic translation initiation factor 4B (UniProt P23588); the current evidence base includes 0 approved drugs, 3 compounds, and 3 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Eukaryotic translation initiation factor 4B
Eukaryotic translation initiation factor 4B Sequence length is 611 aa.
Review this target as Eukaryotic translation initiation factor 4B, mapped to UniProt P23588. Sequence length is 611 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P23588
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 3 compounds, and 3 assays for this target. The dominant activity type is KD. CHEMBL5653589 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL5653589 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Eukaryotic translation initiation factor 4B matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23588, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3
Total Compounds
3
Total Assays
0
Approved Drugs
KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5653589
|
10.0 | Kd | — |
|
|
No preferred name
CHEMBL3752910
|
6.3 | Kd | — |
Source Header